1. Introduction {#sec1}
===============

Beside the well-known choroidal neovascularization (CNV) in the age related macular degeneration (ARMD) in myopic eyes or in angioid streaks, neovascular membranes can develop even as a complication of uveitis with an incidence of 2% \[[@B1]\], accounting for severe visual loss in patients with ocular infectious or noninfectious inflammatory diseases \[[@B2]\], also affecting young patients.

The prevalence of CNV secondary to uveitis varies among different entities, commonly occurring in presumed ocular histoplasmosis (POHS) (3.8%), toxoplasmosis, punctate inner choroidopathy (PIC) (17--40%), idiopathic multifocal choroiditis (MC) (33%), and serpiginous choroiditis (SC) \[[@B2]\]. Yet, CNV has been reported in up to 9% of patients with Vogt-Koyanagi-Harada disease (VKH) \[[@B1], [@B3]\].

2. Diagnosis {#sec2}
============

Inflammatory CNV can develop close to chorioretinal scar or choroidal granuloma and is classified topographically as foveal, juxtafoveal, or extrafoveal. The first is often early recognized by the patient himself complaining of metamorphopsia or central scotoma and can lead to the diagnosis of a subclinical posterior or intermediate uveitis. Otherwise, an extrafoveal membrane may be asymptomatic and can be found only at a follow-up examination or in case of posterior pole acute hemorrhage. As in ARMD, the microscopical features define type 1 or type 2 membrane, if it invades or not the subretinal space. In uveitis the classic membrane strongly shows the main type; it has a grayish appearance with an evidence of exudative or hemorrhagic foci surrounding the lesion. However, opthalmoscopically subretinal membrane could be missed because of very few levels of exudation; the only indirect sign could be a small intraretinal hemorrhagic lesion. Atrophic CNVs are yellow-white plaques. Often a bigger CNV can have a mixed pattern, bearing active foci in a globally fibrous plaque. A membrane can manifest only with macular edema or serous retinal detachment; however, macular edema and serous retinal detachment also can represent signs of inflammation found in course of intermediate/posterior uveitis, leading sometimes to a misdiagnosis or imprecise evaluation of the activity of the underlying disease.

In this case the role of the diagnostic imaging is crucial. Fluorescein angiography (FA) has been for long time the principal way to assess the presence and the activity of a CNV in uveitic patients, showing early hyperfluorescence in the choroidal phase and late leakage, associated sometimes with screen effect in presence of blood or pigment. Indocyanine green angiography (ICG) is useful for highlighting the feeder vessel or occult membranes; the new Heidelberg SLO video ICG enhances the diagnostic potentialities of this procedure. Nowadays a growing role is played by optical coherence tomography (OCT), a fast, noninvasive instrument able to assess the presence and the activity of the disease. Kotsolis et al. \[[@B4]\] showed that FA has a greater capability to detect the membrane features compared to OCT. But in the study of Kotsolis et al. \[[@B4]\] time domain OCT was used mostly; theoretically using the spectral domain OCT this discrepancy is unlikely to be observed, even though a definitive study still lacks.

3. Pathogenesis {#sec3}
===============

Given the low incidence of inflammatory CNV and the difficulty in obtaining a reliable experimental model, most of our knowledge about this disease is mutated from the histopathological studies on ARMD-related CNV, supposing that similar clinical features correspond to common biological pathways.

In CNV a key role of vascular endothelial growth factor (VEGF) in the new blood vessels development has been widely demonstrated \[[@B5], [@B6]\].

VEGF is produced by endothelial cells, pericytes, Müller cells, Ganglion cells, photoreceptors, and RPE cells that can produce the growth factor in a polarized way towards Brüch\'s membrane and choriocapillaris \[[@B7], [@B8]\]. The major signal to the production of these cytokines seems to be the hypoxia via the activation of hypoxia induced factor (HIF) pathways \[[@B9]\]. Four major VEGF isoforms exist: 2 diffusive forms for intercellular signaling (VEGF-121 and VEGF-165) and 2 heparin binding heavier forms (VEGF-189 and VEGF-206) \[[@B10]\]. The cytokines promote secretion of matrix metalloproteinases that cut and activate \[[@B11]\] the VEGF-165 and possibly degrade the extracellular meshwork allowing heavier form to be released and then activated after a plasmin dependent cleavage.

The endothelial progenitor cells (EPCs) are attracted by the stromal cell derived factor 1-alpha (SDF1) that is known to be secreted by hypoxic or damaged retinal pigment epithelium (RPE) or retina \[[@B12], [@B13]\]. The only known receptor for SDF1 is CXCR4 that is expressed on the EPC and is responsible for their chemotaxis toward the damaged tissue. CXCR4 can also be expressed by some leukocytes that are involved in the membrane formation.

Guerin et al. \[[@B14]\] performed a detailed study on CNV of various etiologies, testing some of the most known hypothesis on this subject. There were some unavoidable biases in the study: for example, only advanced and partially fibrous membranes were collected, often unresponsive to the previous therapy. They suggest that RPE cells may play an important role in the development of CNV, the SDF1/CXCR4 axis is present in human, and there is a statistically significant association between detectable SDF1 and the neovascularization marker VEGFR-2.

Furthermore we performed an adjunctive statistical analysis on the dataset reported by Guerin: using Mann-Whitney test (in R environment \[[@B15]\]) we tested if immunohistochemical staining grading of the three main tissues (RPE, vascular network, and fibroblasts) for SDF1, CXCR4, and VEGFR-2 differs between inflammatory CNV and ARMD. In [Table 1](#tab1){ref-type="table"} the *P* values of the comparisons are reported. The study is underpowered for most of the comparisons but, interestingly, a low *P* value was found for the CXCR4 staining of the vascular meshwork of uveitis-related CNV versus ARMD-related CNV, suggesting that capillaries have a different role in the membrane development. Further studies on this distinctive aspect should be necessary.

CNV has also an extravascular component consisting in fibroblasts and leucocytes that express the CXCR4 themselves; furthermore RPE cells showed an increased production of tumor necrosis factor *α* (TNF*α*) and IL-1 \[[@B16]\] recruiting macrophages accounting for the inflammatory component of CNV, and also IL-2, IL-6, and IL-10 have been found, but their role is not clear yet \[[@B17]\].

Other mediators play a role in the membrane development: nitric oxide that induces the membrane formation, besides angiostatin, endostatin, CCR3, and the pigment epithelium derived growth factor (PEDF) contrasting the neovascularization. Focally the membrane can become fibrous and it is thought that the transforming growth factor *β* (TGF-*β*) is responsible for the process of recruiting choroidal fibroblasts, but on the other hand, at the same time, it induces the production of VEGF leading to the formation of new active foci \[[@B18]\].

4. Therapy and Clinical Studies {#sec4}
===============================

Understanding the uveitis as better as possible and identifying underlying infectious diseases are mandatory in order to keep the inflammation under control using the correct medical therapy. The use of steroids and immunosuppressors \[[@B19]\] has shown some utility in preventing and, sometimes, stopping the development of inflammatory CNV, but in the new millennium innovative therapies for ARMD came out and thus were tried on the inflammatory counterpart, leaving argon laser ablation, surgical membrane removal, and macular translocation a marginal role. But the uveitic subretinal membrane is less frequent than the wet ARMD, so researchers cannot freely design comparative studies.

In the literature most of clinical studies on inflammatory CNV therapy are case series with few underpowered retrospective studies often uncontrolled. Commonly patient selection was done in many different ways (naive/treated patients, active/quiescent uveitis, adult/pediatric, and different systemic therapy), making any attempt of rigorous meta-analysis impossible. We focused on the three main therapies available in the last decade: (i) photodynamic therapy (PDT), (ii) intravitreal bevacizumab (IVB), and (iii) intravitreal ranibizumab (IVR). We selected most important published articles in the last ten years with more than 2 subjects and, where possible, we extracted the data of patients. In [Table 2](#tab2){ref-type="table"} we report the name of the first author and the year of publication, the uveitis type included in the study, the median follow-up, where available or calculable, or the median follow-up time as provided in the paper. Moreover, we reported the number of subjects that after the treatment did not lose any line/letter on the total of patients, divided into three columns, one for each therapy, and the median numbers of injections performed or the mean numbers of injections if reported in the study. The articles are ordered by year of publication and then for first author name; at the end of the table we reported the sum and the percentages of success for each therapy in terms of visual acuity (VA) improvement and stabilization. We chose not to perform any statistical analysis on the data because such wide difference between the background studies could give highly biased results. Some well-known articles are not included because we could not extract the data about inflammatory patients only (as in Chang et al.) or because the dataset of patients resembled one of the other published articles by the same group of study.

The first articles report the case series on the PDT; overall success rate is quite high (78.4%) compared to previously reported significative vision loss in untreated patients (77% VA below 20/100) \[[@B51]\]. In most of these studies local or systemic steroid therapy was associated, and in two of them \[[@B25], [@B31]\] immunosuppressive drug was used in the majority of patients. Subsequently in the following years, the use of anti-VEGF therapy increased and IVB became available; 12 case series and 2 comparative retrospective studies about the IVB treatment in uveitis-related CNV are reported (Lott et al. \[[@B38]\] and Cornish et al. \[[@B45]\]). The first compares PDT to IVB in MC and the second IVB to IVR in PIC, but only in few cases. The work of Battaglia-Parodi did not show differences in overall success rate between the two therapies but showed a better visual recovery in patients treated with IVB. The final success rate for IVB seems to be around 87%. Finally in recent years IVR became more used, partly because of the concerns of the off-label use of IVB. We found the final success rate of the latter therapy to be around 90%, not very different by IVB treatment.

Although more than 30 articles were published about the argument, a decision about the treatment of inflammatory CNV cannot be assessed on evidence based medicine, as case series and uncontrolled studies are in the lower half of the scale of scientific evidences. Thus, well-designed randomized clinical trials should be necessary, but a correct comparison between the three main therapeutic strategies would need studies with a large number of people, which is not feasible for a rare complication of a rare disease such as posterior uveitis with strict inclusion and exclusion criteria.

A wise therapeutic approach we may suggest is the following:thorough control of the underlying inflammation using steroids, immunosuppressors, or specific treatment where appropriate;use of PDT for early extrafoveal lesions not causing a decrease in the VA, a less invasive procedure is always preferable in a uveitic eye in order to keep the possibility of flogosis reactivation low;use of IVR for foveal or juxtafoveal membranes or as second line therapy after PDT, the paper of Battaglia-Parodi demonstrated a higher VA for the IVB, but this drug is currently off-label for intravitreal use, and we could expect similar efficacy. Furthermore the literature showed that inflammatory CNV needs much less intravitreal injection than ARMD-related CNV to achieve the complete regression of the membrane.Every year there is the announcement of new therapeutic approaches for wet ARMD, aflibercept, and stereotactic radiotherapy as examples, and the treatment of inflammatory CNV will benefit from these news although again it will be difficult to obtain a specific randomized controlled trial, so necessarily we will have to rely on indirect data.
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###### 

   *P* values of Mann-Whitney test performed on the dataset from Guerin et al. \[[@B14]\] comparing the staining grading for the three molecules studied (SDF1, CXCR4, and VEGFR-2) of the three structures of a CNV.

                             SDF1   CXCR4   VEGFR-2                                       
  -------------------------- ------ ------- --------- ------ ------- ------ ------ ------ ------
  Inflammation versus ARMD   0.92   0.63    0.63      0.92   0.074   0.19   0.41   0.92   0.92

###### 

Overview of the studies on the therapy of inflammatory CNV.

  -------------------------------------------------------------------------------------------------------------------------------------------
  Study (year) \[reference\]                 Uveitis type   FU   PDT        Bevacizumab\                     Ranibizumab\
                                                                            (median numbers of injections)   (median numbers of injections)
  ------------------------------------------ -------------- ---- ---------- -------------------------------- --------------------------------
  Saperstein et al. (2002) \[[@B20]\]        POHS           12   21/25                                        

  Spaide et al. (2002) \[[@B21]\]            MC             10   7/7^§^                                       

  Rogers et al. (2003) \[[@B22]\]            MISC           12   8/9^§^                                       

  Wachtlin et al. (2003) \[[@B23]\]          MISC           22   17/19                                        

  Nessi et al. (2004) \[[@B24]\]             TOXO           3    2/3^§^                                       

  Leslie et al. (2005) \[[@B25]\]            MISC           11   6/6^§‡^                                      

  Parodi et al. (2006) \[[@B26]\]            MC             12   6/7                                          

  Coco et al. (2007) \[[@B27]\]              PIC            23   5/8^§^                                       

  Gerth et al. (2006) \[[@B28]\]             MISC           23   7/14^§^                                      

  Lim et al. (2006) \[[@B29]\]               MISC           12   3/5                                          

  Mauget-Faÿsse (2006) \[[@B30]\]            TOXO           25   6/8                                          

  Nowilaty and Bouhaimed (2006) \[[@B31]\]   VKH            19   4/6^§‡^                                      

  Adán et al. (2007) \[[@B32]\]              MISC           7               8/9 (1)                           

  Chan et al. (2007) \[[@B33]\]              PIC            6               4/4 (3)                           

  Schadlu et al. (2008) \[[@B34]\]           POHS           6               26/28 (1.8\*)\                    
                                                                            most pts. had PDT                

  Priyanka et al. (2009) \[[@B35]\]          MISC           15              4/6 (3)^§^                        

  Tran et al. (2008) \[[@B36]\]              MISC           6               10/10 (2.5)^§‡^                   

  Fine et al. (2009) \[[@B37]\]              MC             6               4/5 (1.5)                         

  Lott et al. (2009) \[[@B38]\]              MISC           7               15/21 (2)^§‡^                     

  Parodi et al. (2010) \[[@B39]\]            MC             12   9/13       12/14 (3.8\*)                     

  Ehrlich et al. (2010) \[[@B40]\]           MISC           9    4/4^§^                                       

  Kramer et al. (2010) \[[@B41]\]            MISC           12              10/10 (2)^§^                      

  Menezo et al. (2010) \[[@B42]\]            PIC            12                                               8/9 (1)^§^

  Arevalo et al. (2011) \[[@B43]\]           MISC           12              21/23 (1)                         

  Carneiro et al. (2011) \[[@B44]\]          MISC           6                                                4/5 (3)

  Cornish et al. (2011) \[[@B45]\]           PIC            12              5/6 (2)                          2/3 (4)

  Juliàn et al. (2011) \[[@B46]\]            MISC           15              12/15 (4.25\*)^§‡^                

  Rouvas et al. (2011) \[[@B47]\]            MISC           17                                               16/16 (2)

  Troutbeck et al. (2012) \[[@B48]\]         MC             12                                               6/7 (3.4\*)

  Iannetti et al. (2013) \[[@B49]\]          MISC           19              7/8 (1)^§^                        

  Mansour et al. (2012) \[[@B50]\]           MISC           36              67/81 (3)                         

                                                                                                             

  Totals (median no of inj.)\                                    105/134\   138/159 (2)\                     36/40 (3)\
  Percentual of success                                          78.4%      86.8%                            90.0%
  -------------------------------------------------------------------------------------------------------------------------------------------

The first column shows the first author name, year of publication, and the reference in square brackets; the second column shows the type of uveitis studied (POHS: presumed ocular histoplasmosis, MC: multifocal choroiditis, MISC: miscellaneous, TOXO: toxoplasmosis, PIC: punctuate inner choroidopathy, and VKH: Vogt-Koyanagi-Harada disease); the third column shows the median follow-up calculated from dataset where not available; in the fourth, fifth, and sixth columns we reported the number of eyes whose VA stabilized or improved with the therapy over the number of eyes treated, respectively, for PDT, IVB, and IVR. Also we indicated the median numbers of injections needed or the mean number\* if reported in the study. In the cells ^‡^indicates more than half patients had immunosuppressive treatment or ^§^for steroid therapy. The last row shows the number of cumulative successes in the eyes treated and the relative percentages. Further statistical analysis was impossible due to the extreme heterogeneity of the studies.
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